Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma | Zendy

Kieron Dunleavy | Zendy; Stefania Pittaluga | Zendy; Lauren S. Maeda | Zendy; Ranjana H. Advani | Zendy; Clara C. Chen | Zendy; Julie Hessler | Zendy; Seth M. Steinberg | Zendy; Clíona Grant | Zendy; George W. Wright | Zendy; Gaurav Varma | Zendy; Louis M. Staudt | Zendy; Elaine S. Jaffe | Zendy; Wyndham H. Wilson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

Author(s) -

Kieron Dunleavy,

Stefania Pittaluga,

Lauren S. Maeda,

Ranjana H. Advani,

Clara C. Chen,

Julie Hessler,

Seth M. Steinberg,

Clíona Grant,

George W. Wright,

Gaurav Varma,

Louis M. Staudt,

Elaine S. Jaffe,

Wyndham H. Wilson

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1214561

Subject(s) - medicine , rituximab , epoch (astronomy) , lymphoma , radiology , oncology , astronomy , stars , physics

Primary mediastinal B-cell lymphoma is a distinct subtype of diffuse large-B-cell lymphoma that is closely related to nodular sclerosing Hodgkin's lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research